Page 6 - Mankind Pharma

Sensex, Nifty end flat after choppy day; Indiabulls RE sinks 20%, Zomato 6%

CLOSING BELL: Among sectors, the Nifty PSU Bank index fell nearly 3 per cent, followed by the Nifty Realty index (close to 1 per cent)

Mankind Pharma lists at 20% premium; should you buy, sell, or hold?

Shares of Mankind listed at Rs 1,300, a 20 per cent premium over its issue price of Rs 1,080 on the National Stock Exchange (NSE) and the BSE

Kansai Nerolac, Canara Bank, Mankind Pharma among top stocks to watch today

Stock to Watch on Tuesday, May 9: Canara Bank's net profit rose 90.6 per cent year-on-year (YoY) at Rs 3,175 crore in Q4FY23

Mankind Pharma to make market debut on Tuesday following a successful IPO

The IPO had seen strong demand from institutional investors even as the retail quota had remained undersubscribed

Sensex leaps 710 pts after a day's hiatus; TaMo, IndusInd rise 5%, PSBs dip

CLOSING BELL: Among sectors, the Nifty Private Bank, Realty, and Auto indices gained around 1.7 per cent each

Mankind Pharma's Rs 4,326-crore IPO garners bids worth Rs 50,000 crore

The Rs 4,326-cr offering garnering bids worth nearly Rs 50,000 cr

Mankind Pharma's initial public offering subscribed 87% on day 2 of issue

Mankind Pharma on Monday allotted shares worth Rs 1,298 crore to 77 anchor investors including 16 domestic mutual funds that participated through 41 schemes

Mankind Pharma's Rs 4,326-crore IPO: Issue subscribed 14% on Day 1

The company's IPO closed on Thursday

Mankind Pharma IPO subscribed 8% so far on Day 1; GMP down 30% in 10 days

The Rs 4,326-crore public issue's price band is set in the range of Rs 1,026-1,080 per share. The issue will close on Thursday, April 27

Mankind Pharma IPO opens today: Check GMP, price band, other details here

Mankind Pharma IPO listing date: The IPO is likely to list on NSE and BSE on May 8

Mankind Pharma raises Rs 1,298 cr from anchor investors ahead of IPO

Canada Pension Plan Investment Board (CPPIB), the Government of Singapore, SBI Multi Cap Fund, and Fidelity Investment Trust were some investors who were allotted shares under the anchor quota

Is Mankind Pharma IPO worth a subscription? Here's what brokerages suggest

In the grey markets, shares of Mankind Pharma enjoyed a premium of Rs 90, which translated to a likely listing price of Rs 1,170 per share on the upper price band

Street signs: Defence stocks may rise, Mankind Pharma IPO, and more

After having recorded seven straight months of outflows, equity savings schemes are expected to witness a change of fortune in the months ahead

Mankind Pharma's Rs 4,326-crore initial public offering to open April 25

The offering is entirely a secondary share sale by promoters, global private equity firm Cairnhill and some other investors of the firm

Mankind Pharma IPO to open next week: Check price band, GMP, other details

Mankind Pharma IPO GMP: According to reports, the IPO is commanding a great market premium of Rs 80 per share today

Top Headlines: Mankind's quality assurance, India in space economy and more

Business Standard brings you the top headlines at this hour

Stocks to Watch: HCL Tech, Lupin, Fusion Micro Fin, Five-Star, NBCC, PNB

Stocks to Watch Today: Newly listed Fusion Micro Finance and Five-Star Business are likely to be in focus on the back of strong Q2 performance reported by the companies.

Mankind Pharma acquires stake in Upakarma Ayurveda for undisclosed sum

Mankind Pharma on Monday said it has acquired a majority stake in Upakarma Ayurveda, engaged in developing, manufacturing and selling ayurvedic and herbal products for an undisclosed amount. The company's decision to invest will empower Upakarma Ayurveda to develop a wider range of products and offerings, the drug firm said in a statement. "The current lifestyle has become strenuous where people find it difficult to focus on their health. To fulfil their requirements, consumers are considering Ayurvedic remedies for long-term sustenance and boosting immunity over time. "As Mankind Pharma works towards improving the healthcare of people, we have associated with Upakarma Ayurveda in order to cater to the emerging needs of consumers," Mankind Pharma Vice Chairman and Managing Director Rajeev Juneja said. Mankind Pharma acquired the ayurvedic soulutions firm through one of its subsidiaries. Upakarma Ayurveda Founder & Managing Director Vishal Kaushik said that with the partnership, ..

Expensive deal valuations to hit Torrent Pharma's near-term earnings

Sales trajectory in domestic formulations and resolution of regulatory issues are other triggers

Mankind Pharma files for IPO, could be second largest among pharma firms

The offer for sale is expected to be anywhere between Rs 5000-5500 crore, say sources